Rakhi Kumar, age 46, has served as a member of our Board of Directors since 2021. From June 2018 through March 2025, Ms. Kumar served as Chief Accounting Officer at Roivant Sciences Ltd., a public biopharmaceutical company, where she led Roivant s accounting and financial operations and related internal controls functions. Ms. Kumar joined Roivant in September 2015, previously serving as Vice President, Finance and External Reporting, from December 2016 to June 2018, and as Senior Director, from September 2015 to December 2016. While at Roivant, led and launched financial operations at Roivant s biopharmaceutical subsidiaries and healthcare technology companies, overseeing treasury, accounting, SOX and financial operations. In her capacity, she also played a pivotal role in guiding the company through multiple successful IPOs and was heavily involved in significant transactions, such as the go-public activities at Immunovant and Roivant via a SPAC, Roivant's $3B strategic alliance with Sumitomo Dainippon Pharma, Roivant s $7.1B sale of Telavant to Roche and Roivant s $1.2B sale of Dermavant to Organon. Ms. Kumar has also served on the board of directors of Roivant Social Ventures since 2018. Prior to joining Roivant, Ms. Kumar was with The Medicines Company, which was acquired by Novartis, from June 2013 to September 2015, where she was responsible for external reporting and corporate and technical accounting. Earlier in her career, Ms. Kumar was in the assurance services at Ernst and Young. Ms. Kumar earned an M.S in Accounting and Taxation from the University of Hartford. Ms. Kumar is a member of the Financial Accounting Standards Board s Small Business Advisory Committee. She is a certified public accountant and a Chartered Professional Accountant in Ontario, Canada. We believe Ms. Kumar is qualified to serve on our Board of Directors because of her leadership and extensive life sciences industry experience.